Lupin Receives US FDA EIR for Ankleshwar Manufacturing Site
MUMBAI, India, May 28, 2026 Lupin Limited, one of the world’s leading pharmaceutical companies, has announced that it has...
Alzheimer’s Disease ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
MUMBAI, India, May 28, 2026 Lupin Limited, one of the world’s leading pharmaceutical companies, has announced that it has...
SUZHOU, China, May 26, 2026 WuXi Vaccines, a wholly owned subsidiary of WuXi Biologics specializing in vaccine Contract Development...
COLUMBUS, Ohio, May 13, 2026 Andelyn Biosciences announced that it has received full certification under the Initiative for Certification...
WESTON, FLORIDA, USA, April 14, 2026 Apotex Corp., in collaboration with Orbicular Pharmaceutical Technologies Pvt. Ltd. and Gland Pharma...
Mumbai, India & Naples, Florida | April 10, 2026 Lupin Limited has announced the U.S. launch of Dapagliflozin Tablets...
WINNIPEG, Manitoba, April 9, 2026 Emergent BioSolutions Inc. has announced a strategic partnership with the British Columbia Provincial Health...
HERZLIYA, Israel, March 17, 2026 Regentis Biomaterials Ltd. has announced a breakthrough solvent-free manufacturing process for its lead regenerative...
Ottawa, Canada — February 6, 2026 Health authorities have issued a public advisory announcing the recall of two lots...
INDIANAPOLIS / LEHIGH VALLEY, Pa., Jan. 30, 2026 — Eli Lilly announced plans to invest more than $3.5 billion...
WUXI, China, Jan. 4, 2026 — WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced...
